Notably, YTHDF1 knockdown increased the sensitivity of glioma cells to the antiproliferative effects of TMZ, demonstrating its potential as a synergistic target for improved treatment response in GBM. The gene discussed is YTHDF1; the disease is central nervous system cancer.